Granulocyte colony-stimulating factor-induced mobilization of peripheral blood stem cells for autologous and allogeneic transplantation. Fukuoka Bone Marrow Transplantation Group. 1996

M Harada, and T Teshima, and T Fujisaki, and S Mizuno, and T Miyamoto, and Y Takamatsu, and A Kubota, and Y Ohno, and M Kuroiwa, and K Takenaka, and T Eto, and K Akashi, and H Gondo, and T Okamura, and S Inaba, and Y Niho
Second Department of Internal Medicine, Okayama University Medical School, Japan.

Peripheral blood stem and progenitor cells (PBSC and PBPC), which circulate at very low levels during steady-state hematopoiesis, show a transient but marked increase during hematologic recovery from marrow-suppressive chemotherapy. To ensure rapid and sustained hematologic engraftment after autologous PBSC transplantation, sufficient PBSC or PBPC must be infused. To confirm the utility of granulocyte colony-stimulating factor (G-CSF) in chemotherapy-induced PBSC mobilization, we investigated the effect of G-CSF on PBSC mobilization in leukemia and lymphoma patients. The study design was such that PBSC mobilization with and without G-CSF was assessed in the same patients. The results indicate that PBSC mobilization can be enhanced significantly when G-CSF is given during the recovery phase postchemotherapy. Interestingly, progenitor cells of different lineages could be mobilized by G-CSF. We subsequently investigated the effect of increasing G-CSF dose on PBSC mobilization during steady-state hematopoiesis in healthy adult donors. The results indicate that not only committed but also primitive progenitor cells are mobilized into the circulation in a dose-and time-dependent manner when G-CSF at 5, 10, or 15 micrograms/kg was given on each of 5 days and leukapheresis was performed on day 6. From our data we estimate that sufficient PBSC for engraftment after allogeneic PBSC transplantation can be collected on day 5 of administration of G-CSF at 10 micrograms/kg and by 10-1 leukapheresis on days 5 and 6. Furthermore, we found that some G-CSF-mobilized PBSC retained their self-renewal capability. These observations suggest that hematopoietic stem cells for allogeneic PBSC transplantation can be mobilized by short-term administration of relatively high-dose G-CSF.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D006412 Hematopoietic Stem Cells Progenitor cells from which all blood cells derived. They are found primarily in the bone marrow and also in small numbers in the peripheral blood. Colony-Forming Units, Hematopoietic,Progenitor Cells, Hematopoietic,Stem Cells, Hematopoietic,Hematopoietic Progenitor Cells,Cell, Hematopoietic Progenitor,Cell, Hematopoietic Stem,Cells, Hematopoietic Progenitor,Cells, Hematopoietic Stem,Colony Forming Units, Hematopoietic,Colony-Forming Unit, Hematopoietic,Hematopoietic Colony-Forming Unit,Hematopoietic Colony-Forming Units,Hematopoietic Progenitor Cell,Hematopoietic Stem Cell,Progenitor Cell, Hematopoietic,Stem Cell, Hematopoietic,Unit, Hematopoietic Colony-Forming,Units, Hematopoietic Colony-Forming
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016179 Granulocyte Colony-Stimulating Factor A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. Colony-Stimulating Factor, Granulocyte,G-CSF,Myeloid Growth Factor,Colony Stimulating Factor, Granulocyte,Factor, Granulocyte Colony-Stimulating,Factor, Myeloid Growth,Granulocyte Colony Stimulating Factor,Growth Factor, Myeloid
D018380 Hematopoietic Stem Cell Transplantation Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms. Stem Cell Transplantation, Hematopoietic,Transplantation, Hematopoietic Stem Cell

Related Publications

M Harada, and T Teshima, and T Fujisaki, and S Mizuno, and T Miyamoto, and Y Takamatsu, and A Kubota, and Y Ohno, and M Kuroiwa, and K Takenaka, and T Eto, and K Akashi, and H Gondo, and T Okamura, and S Inaba, and Y Niho
June 1996, Medical and pediatric oncology,
M Harada, and T Teshima, and T Fujisaki, and S Mizuno, and T Miyamoto, and Y Takamatsu, and A Kubota, and Y Ohno, and M Kuroiwa, and K Takenaka, and T Eto, and K Akashi, and H Gondo, and T Okamura, and S Inaba, and Y Niho
December 1989, Japanese journal of clinical oncology,
M Harada, and T Teshima, and T Fujisaki, and S Mizuno, and T Miyamoto, and Y Takamatsu, and A Kubota, and Y Ohno, and M Kuroiwa, and K Takenaka, and T Eto, and K Akashi, and H Gondo, and T Okamura, and S Inaba, and Y Niho
September 1994, Blood,
M Harada, and T Teshima, and T Fujisaki, and S Mizuno, and T Miyamoto, and Y Takamatsu, and A Kubota, and Y Ohno, and M Kuroiwa, and K Takenaka, and T Eto, and K Akashi, and H Gondo, and T Okamura, and S Inaba, and Y Niho
December 2019, Clinical hematology international,
M Harada, and T Teshima, and T Fujisaki, and S Mizuno, and T Miyamoto, and Y Takamatsu, and A Kubota, and Y Ohno, and M Kuroiwa, and K Takenaka, and T Eto, and K Akashi, and H Gondo, and T Okamura, and S Inaba, and Y Niho
January 2008, Journal of clinical apheresis,
M Harada, and T Teshima, and T Fujisaki, and S Mizuno, and T Miyamoto, and Y Takamatsu, and A Kubota, and Y Ohno, and M Kuroiwa, and K Takenaka, and T Eto, and K Akashi, and H Gondo, and T Okamura, and S Inaba, and Y Niho
March 1993, Blood,
M Harada, and T Teshima, and T Fujisaki, and S Mizuno, and T Miyamoto, and Y Takamatsu, and A Kubota, and Y Ohno, and M Kuroiwa, and K Takenaka, and T Eto, and K Akashi, and H Gondo, and T Okamura, and S Inaba, and Y Niho
May 2000, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
M Harada, and T Teshima, and T Fujisaki, and S Mizuno, and T Miyamoto, and Y Takamatsu, and A Kubota, and Y Ohno, and M Kuroiwa, and K Takenaka, and T Eto, and K Akashi, and H Gondo, and T Okamura, and S Inaba, and Y Niho
November 1990, Blood,
M Harada, and T Teshima, and T Fujisaki, and S Mizuno, and T Miyamoto, and Y Takamatsu, and A Kubota, and Y Ohno, and M Kuroiwa, and K Takenaka, and T Eto, and K Akashi, and H Gondo, and T Okamura, and S Inaba, and Y Niho
May 2002, Current opinion in hematology,
M Harada, and T Teshima, and T Fujisaki, and S Mizuno, and T Miyamoto, and Y Takamatsu, and A Kubota, and Y Ohno, and M Kuroiwa, and K Takenaka, and T Eto, and K Akashi, and H Gondo, and T Okamura, and S Inaba, and Y Niho
March 1995, Blood,
Copied contents to your clipboard!